Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens

NCT05370521 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT05370521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05370521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
Lead sponsor
Spruce Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
May 15, 2022
Completion date
August 31, 2023
Enrollment
27 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic ovary syndrome